knowledge -WSS

knowledge

author：fashion 2025-09-29 22:50:33 - browse：934

Illustration of a dollar sign with arrows. — Adobe

Health insurers are telling shareholders that they are ramping up the use of artificial intelligence and are hiring talent to implement the technology across their organizations. They say their artificial intelligence models can increase efficiency and “cut costs,” but they refused to discuss what models they’re using, how those models were developed, or exactly what they’re using them for.

Centene, for instance, says, it is “investing in artificial intelligence and machine learning technologies to improve the health of our members and contain rising healthcare costs.” The insurer, whose plans cover more than 28 million Americans, noted that its large footprint, particularly in government-sponsored programs, puts it “in a unique position to use data to develop models that predict a wide range of health outcomes.”

A STAT review of regulatory filings from publicly traded health insurers showed that several of them, including Elevance, Molina, and Cigna, are investing in AI with the goal of saving money. Elevance has hired nearly 500 people to work exclusively on AI. However, all five of the insurers STAT contacted declined to elaborate on how they are using AI.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： What the Wegovy shortage looks like for doctors — and for patients

WSS

Thermo Fisher plant for manufacturing gene therapies to expand

Thermo Fisher plant for manufacturing gene therapies to expand

How should state employee insurance handle Wegovy?

Hearing on Medicare drug price negotiation gets unusually heated

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

Humana CEO Bruce Broussard to step down in 2024

hotspot

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

focus

Trump demands the U.S. pay no more for drugs than other countries … again

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

STAT Virtual Event: Putting AI to the Test

At least 13 dead in Texas as scorching temps continue

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

The cancer drug shortage isn’t new — and neither are the solutions

How clinical AI models' predictive power can degrade over time

Hepatitis C has a cure — but many Americans still lack access to it

Drug for rare kidney disease narrowly misses mark in clinical trial

explore

Wellcome Trust names Røttingen as its new CEO

Wellcome Trust names Røttingen as its new CEO

Better Therapeutics data on benefit with GLP

Changes to biosimilar regulatory framework must prioritize patients

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

How clinical AI models' predictive power can degrade over time

hotspot

focus

Wikipedia

focus